Research Article
BibTex RIS Cite

IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?

Year 2017, Volume: 5 Issue: 2, 85 - 92, 25.12.2017
https://doi.org/10.24998/maeusabed.346213

Abstract

İnterlöykin- 6 (IL-6) hücre
sağ kalımı, çoğalması, farklılaşması, bağışıklık ve apoptosis gibi birçok
hücresel olayda önemli rol oynar. Il-6 hem konakçı
bağışıklık savunma mekanizması hem de büyüme ve farklılaşma gibi çeşitli
malignitelerin düzenlenmesinde yer almaktadır.
Daha önce yapılan
çalışmalar,  artmış serum IL- 6
düzeylerinin birçok kanser türünde ilerlemiş tümör evreleri ve hastalarda kısa
hayatta kalım süreleri ile ilişkili olduğunu ortaya koymuştur. Sunulan
çalışmada IL-6 ‘nın HepG2 hücrelerinde kaspaz 3, kaspaz,9 ve kaspaz 1
aktiviteleriüzerine
etkilerinin araştırılması amaçlanmıştır.Çalışma materyali olarak hepatoselüler
karsinoma hücre hatta olan HepG2 hücreleri kullanılmıştır. IL-6 uygulanan ve
uygulanmayan (kontrol) hücreler 24 saat boyunca kültüre edilmiş. IL-6 ‘nın
HepG2 hücrelerinde kaspaz 3, kaspaz,9 ve kaspaz 1 düzeyleri üzerine etkileri
ticari kit ile kolorimetrik olarak ölçülmüştür. IL-6 uygulanan HepG2
hücrelerinde kaspaz 1 ve kaspaz 3 düzeyleri kontrol hücrelerine göre artmış
kaspaz 9 düzey
leri ise azalmıştır.Daha önce yapılan çalışma
sonuçları IL-6’nın tümör hücrelerinde hücre çoğalmasını ve anti-apoptotik etki
arttırmak gibi, önemli tümör gelişimini destekleyici özelliklerinin bulunduğunu
göstermiştir. Bilinenin aksine, kaspaz 3 aktivitesinin artışı ile, IL-6 ilavesi
HepG2 hücrelerinde apoptotik yolak üzerinde etkili olduğu görülmüştür.

References

  • Abou-Shousha, S, Moaaz, M, Sheta, M, Motawea, MA, 2016. An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti-Interleukin-6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma. Scandinavian Journal of Immunology. 83: 427–437.
  • Akira S, Hirano T, Taga T, Kishimoto T, 1990. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4(11):2860-7.
  • Anonim, 2017 b http://www.hepg2.com/ erişim: 05.10.2017.
  • Anonim, 2017a http://kanser.gov.tr/kanser/kanser-nedir/4-kanser-nedir.htmlerişim: 05.10.2017.
  • Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY, 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 88: 1721–6.
  • Balkwill F, Mantovani A, 2001. Inflammation and cancer: Back to Virchow?. Lancet. 357: 539-545.
  • Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B, 2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 85: 3338-3342.
  • Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdoğan M, Artaç M, Altunbaş H, Akan İ, Savaş B, 2004. Tumor necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy, Cytokine. 27: 58–65.
  • Dranoff G, 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 4: 1- 22.
  • Guegan C, Vila M, Teismann P, Chen C, Onteniente B, Li M, Friedlander R, Przedborski S, 2002. Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS, Mol Cell Neurosci. 20: 553–562.
  • Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM, 1998. Caspase-14 is a novel developmentally regulated protease, J Biol Chem. 273:29648–53.
  • Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G, 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 368: 339- 342.
  • Kurzrock R,Voorhees P, Fayad L,Orlowski R, Van Rhee F, Furman R,Borghaei H, Zaki MH, Prabhakar U, Garay C,2006. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in patients with selected hematologic malignancies. J Clin Oncol. 24: 2513
  • Leu CM, Wong FH, Chang C, Huang SF, Hu CP, 2003. Interleukin-6 acts as an anti-apoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22(49): 7809–18.
  • Lİ W, Tian YH, Liu Y, Wang Z, Tang S, Zhang J, Wang YP, 2016. Platycodin D exerts anti-tumor efficacy in H22 tumor-bearing mice via improving immun function and inducing apoptosis. J. Toxicol. Sci. 41(3): 417-428.
  • Lin WW, Karin M, 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest. 117: 1175–1183.
  • Mantovani A, Pierotti MA, 2008. Cancer and inflammation: a complex relationship, Cancer Lett. 267: 180–1.
  • Mantovani A, Romero P, Palucka AK, Marincola FM, 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 371: 771–83.
  • Mauer J, Denson JL, Bruning JC, 2015. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol, 36(2): 92-101.
  • McIlwain DR, Berger T, Mak TW, 2013. Caspase Functions in Cell Death and Disease, Cold Spring Harb Perspect Biol. 5, a008656
  • McIlwain DW, Zoetemelk M, Myers JD, Edwards MT, Snider BM, Jerde TJ, 2016. Coordinated Induction of Cell Survival Signaling in the Inflamed Microenvironment of the Prostate, The Prostate. 76: 722–734.
  • Minichsdorfer C, Wasinger C, Sieczkowski E, Atil B, Hohenegger M, 2015. Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells, Melanoma Research. 25: 284–294.
  • Nicholson DW, 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6: 1028-1042.
  • Van de Craen M, Declercq W, Van den brande I. Fiers W, Vandenabeele P,1999. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 6(11): 1117–24.
Year 2017, Volume: 5 Issue: 2, 85 - 92, 25.12.2017
https://doi.org/10.24998/maeusabed.346213

Abstract

References

  • Abou-Shousha, S, Moaaz, M, Sheta, M, Motawea, MA, 2016. An Approach to Breast Cancer Immunotherapy: The Apoptotic Activity of Recombinant Anti-Interleukin-6 Monoclonal Antibodies in Intact Tumour Microenvironment of Breast Carcinoma. Scandinavian Journal of Immunology. 83: 427–437.
  • Akira S, Hirano T, Taga T, Kishimoto T, 1990. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4(11):2860-7.
  • Anonim, 2017 b http://www.hepg2.com/ erişim: 05.10.2017.
  • Anonim, 2017a http://kanser.gov.tr/kanser/kanser-nedir/4-kanser-nedir.htmlerişim: 05.10.2017.
  • Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY, 2003. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer. 88: 1721–6.
  • Balkwill F, Mantovani A, 2001. Inflammation and cancer: Back to Virchow?. Lancet. 357: 539-545.
  • Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B, 2000. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 85: 3338-3342.
  • Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdoğan M, Artaç M, Altunbaş H, Akan İ, Savaş B, 2004. Tumor necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy, Cytokine. 27: 58–65.
  • Dranoff G, 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 4: 1- 22.
  • Guegan C, Vila M, Teismann P, Chen C, Onteniente B, Li M, Friedlander R, Przedborski S, 2002. Instrumental activation of bid by caspase-1 in a transgenic mouse model of ALS, Mol Cell Neurosci. 20: 553–562.
  • Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM, 1998. Caspase-14 is a novel developmentally regulated protease, J Biol Chem. 273:29648–53.
  • Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G, 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 368: 339- 342.
  • Kurzrock R,Voorhees P, Fayad L,Orlowski R, Van Rhee F, Furman R,Borghaei H, Zaki MH, Prabhakar U, Garay C,2006. Phase I, multicenter trial of CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) in patients with selected hematologic malignancies. J Clin Oncol. 24: 2513
  • Leu CM, Wong FH, Chang C, Huang SF, Hu CP, 2003. Interleukin-6 acts as an anti-apoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22(49): 7809–18.
  • Lİ W, Tian YH, Liu Y, Wang Z, Tang S, Zhang J, Wang YP, 2016. Platycodin D exerts anti-tumor efficacy in H22 tumor-bearing mice via improving immun function and inducing apoptosis. J. Toxicol. Sci. 41(3): 417-428.
  • Lin WW, Karin M, 2007. A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest. 117: 1175–1183.
  • Mantovani A, Pierotti MA, 2008. Cancer and inflammation: a complex relationship, Cancer Lett. 267: 180–1.
  • Mantovani A, Romero P, Palucka AK, Marincola FM, 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 371: 771–83.
  • Mauer J, Denson JL, Bruning JC, 2015. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol, 36(2): 92-101.
  • McIlwain DR, Berger T, Mak TW, 2013. Caspase Functions in Cell Death and Disease, Cold Spring Harb Perspect Biol. 5, a008656
  • McIlwain DW, Zoetemelk M, Myers JD, Edwards MT, Snider BM, Jerde TJ, 2016. Coordinated Induction of Cell Survival Signaling in the Inflamed Microenvironment of the Prostate, The Prostate. 76: 722–734.
  • Minichsdorfer C, Wasinger C, Sieczkowski E, Atil B, Hohenegger M, 2015. Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells, Melanoma Research. 25: 284–294.
  • Nicholson DW, 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ. 6: 1028-1042.
  • Van de Craen M, Declercq W, Van den brande I. Fiers W, Vandenabeele P,1999. The proteolytic procaspase activation network: an in vitro analysis. Cell Death Differ. 6(11): 1117–24.
There are 24 citations in total.

Details

Subjects Health Care Administration
Journal Section Research Article
Authors

Burcu Menekşe Balkan

Görkem Kısmalı This is me

Deniz Turan This is me

Ali Burak Balkan This is me

Tevhide Sel

Publication Date December 25, 2017
Submission Date October 24, 2017
Published in Issue Year 2017 Volume: 5 Issue: 2

Cite

APA Balkan, B. M., Kısmalı, G., Turan, D., Balkan, A. B., et al. (2017). IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?. Mehmet Akif Ersoy University Journal of Health Sciences Institute, 5(2), 85-92. https://doi.org/10.24998/maeusabed.346213
AMA Balkan BM, Kısmalı G, Turan D, Balkan AB, Sel T. IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?. Mehmet Akif Ersoy University Journal of Health Sciences Institute. December 2017;5(2):85-92. doi:10.24998/maeusabed.346213
Chicago Balkan, Burcu Menekşe, Görkem Kısmalı, Deniz Turan, Ali Burak Balkan, and Tevhide Sel. “IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?”. Mehmet Akif Ersoy University Journal of Health Sciences Institute 5, no. 2 (December 2017): 85-92. https://doi.org/10.24998/maeusabed.346213.
EndNote Balkan BM, Kısmalı G, Turan D, Balkan AB, Sel T (December 1, 2017) IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?. Mehmet Akif Ersoy University Journal of Health Sciences Institute 5 2 85–92.
IEEE B. M. Balkan, G. Kısmalı, D. Turan, A. B. Balkan, and T. Sel, “IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?”, Mehmet Akif Ersoy University Journal of Health Sciences Institute, vol. 5, no. 2, pp. 85–92, 2017, doi: 10.24998/maeusabed.346213.
ISNAD Balkan, Burcu Menekşe et al. “IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?”. Mehmet Akif Ersoy University Journal of Health Sciences Institute 5/2 (December 2017), 85-92. https://doi.org/10.24998/maeusabed.346213.
JAMA Balkan BM, Kısmalı G, Turan D, Balkan AB, Sel T. IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?. Mehmet Akif Ersoy University Journal of Health Sciences Institute. 2017;5:85–92.
MLA Balkan, Burcu Menekşe et al. “IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?”. Mehmet Akif Ersoy University Journal of Health Sciences Institute, vol. 5, no. 2, 2017, pp. 85-92, doi:10.24998/maeusabed.346213.
Vancouver Balkan BM, Kısmalı G, Turan D, Balkan AB, Sel T. IL-6 İlavesi HEPG2 Hücrelerinde Kaspaz Aktivitelerini Nasıl Etkiler?. Mehmet Akif Ersoy University Journal of Health Sciences Institute. 2017;5(2):85-92.